# EDGAR Filing Document

**Accession Number:** 0002080625
**File Stem:** 0000950170-25-111757
**Filing Date:** 2025-8
**Character Count:** 10434
**Document Hash:** a1573dce68629283b0b59e37364240de
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-25-111757.hdr.sgml**: 20250827

**ACCESSION NUMBER**: 0000950170-25-111757

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250718

**FILED AS OF DATE**: 20250827

**DATE AS OF CHANGE**: 20250827

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Kline Kyle
- **CENTRAL INDEX KEY:** 0002080625

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-35621
- **FILM NUMBER:** 251266762

**MAIL ADDRESS:**
- **STREET 1:** 2560 GENERAL ARMISTEAD AVE
- **CITY:** AUDUBON
- **STATE:** PA
- **ZIP:** 19403
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** GLOBUS MEDICAL INC
- **CENTRAL INDEX KEY:** 0001237831
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 043744954
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 2560 GENERAL ARMISTEAD AVENUE
- **CITY:** AUDUBON
- **STATE:** PA
- **ZIP:** 19403
- **BUSINESS PHONE:** 610-930-1800

**MAIL ADDRESS:**
- **STREET 1:** 2560 GENERAL ARMISTEAD AVENUE
- **CITY:** AUDUBON
- **STATE:** PA
- **ZIP:** 19403

## Ex-24

Know all by these presents that the undersigned hereby constitutes and appoints each of<br>Kelly G. Huller and Adam M. Cole, and each of them acting alone, signing singly, the<br>undersigned's true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned,<br>in the undersigned's capacity as an officer, director and/or 10% or more stockholder of Globus<br>Medical, Inc. (the "Company"), Forms ID, 3, 4, 5 and Update Passphrase Acknowledgement (and<br>any amendments thereto) in accordance with Section 16(a) of the Securities Exchange Act of 1934,<br>as amended (the "1934 Act"), and the rules promulgated thereunder; (2) do and perform any and<br>all acts for and on behalf of the undersigned which may be necessary or desirable to complete and<br>execute any such Form ID, 3, 4, 5 and Update Passphrase Acknowledgement (and any amendments<br>thereto) and to file timely such form with the United States Securities and Exchange Commission<br>and any stock exchange or similar authority; and (3) take any other action of any type whatsoever<br>in connection with the foregoing which in the opinion of such attorney-in-fact may be of benefit<br>to, in the best interest of, or legally required by, the undersigned, it being understood that the<br>documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power<br>of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

<br>The undersigned hereby grants to such attorney-in-fact full power and authority to do and<br>perform any and every act and thing whatsoever requisite, necessary or proper to be done in the<br>exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the<br>undersigned might or could do if personally present, with full power of substitution or revocation,<br>hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute<br>or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the<br>rights and powers herein granted. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of the undersigned, is not assuming, nor is the<br>Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the<br>1934 Act.

<br>This Power of Attorney revokes any and all prior powers of attorney and shall remain in<br>full force and effect until the undersigned is no longer required to file Forms ID, 3, 4 and 5 with<br>respect to the undersigned's holdings of and transactions in securities issued by the Company,<br>unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorney-in-fact.<br>

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be<br>executed as of this 8th day of August 2025.

/s/ Kyle Kline<br>______________________________________________________<br>Signature

Kyle Kline<br>________________________________________________<br>Print Name

------

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Kline Kyle<br><sub>(Last) (First) (Middle)</sub><br>VALLEY FORGE BUSINESS CENTER<br>2560 GENERAL ARMISTEAD AVENUE<br><sub>(Street)</sub><br>AUDUBON, PA 19403<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>GLOBUS MEDICAL INC [ GMED ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2025-07-18 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_Senior Vice President, CFO_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Stock Option (Right to Buy Class A Common Stock) | <sup>(1)</sup> | 2031-01-25 | Class A Common Stock | 5000 | $64.44 | D |  |
| Stock Option (Right to Buy Class A Common Stock) | <sup>(2)</sup> | 2031-08-09 | Class A Common Stock | 5000 | $80.17 | D |  |
| Stock Option (Right to Buy Class A Common Stock) | <sup>(3)</sup> | 2032-01-27 | Class A Common Stock | 5000 | $63.68 | D |  |
| Stock Option (Right to Buy Class A Common Stock) | <sup>(4)</sup> | 2033-03-24 | Class A Common Stock | 5000 | $53.14 | D |  |
| Stock Option (Right to Buy Class A Common Stock) | <sup>(5)</sup> | 2034-02-27 | Class A Common Stock | 15000 | $56.43 | D |  |
| Stock Option (Right to Buy Class A Common Stock) | <sup>(6)</sup> | 2034-03-14 | Class A Common Stock | 7500 | $51.87 | D |  |
| Stock Option (Right to Buy Class A Common Stock) | <sup>(7)</sup> | 2035-01-30 | Class A Common Stock | 9091 | $93.12 | D |  |

---

### Footnotes:

(1) These options were granted on January 25, 2021, and vest over a four-year period with one-fourth (1/4) of the options granted vesting on January 1, 2022, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months.

(2) These options were granted on August 9, 2021, and vest over a four-year period with one-fourth (1/4) of the options granted vesting on July 12, 2022, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months.

(3) These options were granted on January 27, 2022, and vest over a four-year period with one-fourth (1/4) of the options granted vesting on January 1, 2023, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months.

(4) These options were granted on March 24, 2023, and vest over a four-year period with one-fourth (1/4) of the options granted vesting on January 1, 2024, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months.

(5) These options were granted on February 27, 2024, and vest over a four-year period with one-fourth (1/4) of the options granted vesting on January 1, 2025, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months.

(6) These options were granted on March 14, 2024, and vest over a four-year period with one-fourth (1/4) of the options granted vesting on January 1, 2025, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months.

(7) These options were granted on January 30, 2025, and vest over a four-year period with one-fourth (1/4) of the options granted vesting on January 1, 2026, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months.

**Signature:** /s/ Kelly G. Huller, Attorney-in-Fact  
**Date:** 2025-08-27

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**